Reviewing the Compounding Risks for Tuberculosis Drug-Induced Liver Injury in a Patient with Transfusion Dependent Thalassaemia

Article Sidebar

PDF
Published: Jul 31, 2023
DOI: https://doi.org/10.47836/mjmhs19.4.51
Keywords:
Antitubercular agents, Case report, Drug-induced liver injury, Tuberculosis, Thalassaemia major

Main Article Content

Nursafinas Rofii
Department of Medicine, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Ummi Nadira Daut
Department of Medicine, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia
Su Yin Lau
Department of Medicine, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Serdang, Selangor, Malaysia

Abstract

A patient presents with jaundice three weeks into commencement of anti-tuberculosis therapy (ATT). Tuberculosis drug-induced liver injury (TB-DILI) is a main concern in patients commencing ATT. Studies have reported various risk factors associated with TB-DILI, urging vigilance in monitoring liver enzymes in these patients. We aim to review the causes of jaundice in a patient with transfusion dependent thalassaemia commenced on ATT and highlight the risk factors associated with TB-DILI.

Downloads

Download data is not yet available.

Article Details

How to Cite
Rofii, N., Daut, U. N., & Lau, S. Y. (2023). Reviewing the Compounding Risks for Tuberculosis Drug-Induced Liver Injury in a Patient with Transfusion Dependent Thalassaemia. Malaysian Journal of Medicine and Health Sciences, 19(4), 365–367. https://doi.org/10.47836/mjmhs19.4.51
Issue
Vol. 19 No. 4 (2023)
Section
Case Report
Crossref
Scopus
Google Scholar
Europe PMC

References

Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806-15. doi: 10.1038/clpt.2011.58.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52. doi:10.1164/rccm.200510-1666ST.

Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut. 1972;13(5):366–71. doi: 10.1136/gut.13.5.366.

Patterson B, Abbara A, Collin S, Henderson M, Shehata M, Gorgui-Naguib H, et al. Predicting drug-induced liver injury from anti-tuberculous medications by early monitoring of liver tests. Journal of Infection. 2021;82(2):240–4. doi: 10.1016/j.jinf.2020.09.038

Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Müllhaupt B, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 2009 Oct;51(4):655–66. doi: 10.1016/j.jhep.2009.05.016